Dartmouth researchers achieve better long-term control of drug-resistant breast cancer growth in mice by switching between estrogen and anti-estrogen therapies.
Post Tagged with: "breast cancer"
A team of researchers at Geisel, led by Glyn Elwyn, MD, PhD, MSc, has received a $2.1 million funding award from the Patient-Centered Outcomes Research Institute to develop a shared decision-making process to help women with breast cancer choose between surgical treatments.
A common anti-diabetes drug being tested in many clinical trials as an anti-cancer agent activated fat metabolism that promoted the survival of dormant breast cancer cells, suggesting that the drug has context-dependent effects on cancer cells.
A new study by scientists at Dartmouth’s Norris Cotton Cancer Center and the Dartmouth Institute for Health Policy and Clinical Practice conducted focus groups with women in three different states to learn what they did and did not know about breast density, in general and their own. The study found that women had varying knowledge. What they all had in common was a strong desire to learn more.
Scientists at Dartmouth’s Norris Cotton Cancer Center make a direct connection between dietary fat and cancer cell biology by showing that fat particles from the blood are taken into breast cancer cells through a novel mechanism.
Dartmouth researchers have found a machine learning method that can predict the likelihood that a high-risk type of breast lesion is cancerous, potentially saving some women from unnecessary surgeries and overtreatment.
A newly published collaborative national study finds that most women with two or three sites of cancer in a single breast can successfully complete breast conservation therapy rather than mastectomy.
A research team at The Dartmouth Institute for Health Policy and Clinical Practice has received a $2 million funding award from the Patient-Centered Outcomes Research Institute (PCORI) to conduct a research project that is likely to change the way women and their doctors make decisions about breast cancer surgery.
Dartmouth SYNERGY Clinical and Translational Science Institute has appointed Richard J. Barth, Jr., MD, as the first recipient of its SYNERGY Clinician-Entrepreneur Fellowship (S-CEF). The S-CEF will provide Dr. Barth with resources and dedicated time to develop and study the commercial potential of a new system to improve certain types of breast cancer surgery.
Thanks to a $100,000, two-year grant from the Mary Kay Foundation, Geisel researchers are launching a study to identify the biological mechanisms that allow clinically dormant ER+ breast cancer cells to survive anti-estrogen therapy.